Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy

Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy

Abstract Resistance to sorafenib severely hinders its effectiveness against hepatocellular carcinoma (HCC). Cancer stemness is closely connected with resistance to sorafenib. Methods for reversing the cancer stemness remains one of the largest concerns in research and the lack of such methods obstru...

Full description

Bibliographic Details
Main Authors: Shengjun Xu, Sunbin Ling, Qiaonan Shan, Qianwei Ye, Qifan Zhan, Guangjiang Jiang, Jianyong Zhuo, Binhua Pan, Xue Wen, Tingting Feng, Haohao Lu, Xuyong Wei, Haiyang Xie, Shusen Zheng, Jiajia Xiang, Youqing Shen, Xiao Xu
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Advanced Science
Subjects:
cascade‐responsive
co‐delivery
hepatocellular carcinoma
sorafenib
USP22 shRNA
Online Access:https://doi.org/10.1002/advs.202003042

Internet

https://doi.org/10.1002/advs.202003042

Similar Items